Mutation of the p53 gene in human astrocytic tumours correlates with increased resistance to DNA-damaging agents but not to anti-microtubule anti-cancer agents

British Journal of Cancer

Volumn 77, Issue 4, 1998, Pages 547-551

  Iwadate, Y ^a   Tagawa, M ^b   Fujimoto, S ^b   Hirose, M ^b   Namba, H ^b   Sueyoshi, K ^b   Sakiyama, S ^b   Yamaura, A ^a  

^a CHIBA UNIVERSITY   (Japan)

^b CHIBA CANCER CENTER   (Japan)

Author keywords

Astrocytic tumour; Chemosensitivity; DNA damage; Microtubule; p53

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN P53;

ARTICLE; ASTROCYTE; CELL DEATH; DRUG SENSITIVITY; FLOW CYTOMETRY; GENE MUTATION; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM;

EID: 0031985148     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.88     Document Type: Article

References (22)

1. Ass T, Børresen A-L, Geisler S, Smith-Sørensen B, Johnsen H, Varhaug JE, Akslen LA and Lønning PE (1996) Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature Med 2: 811-814
2. Chamberlain MC and Kormanik P (1995) Salvage chemotherapy with paclitaxel for recurrent primary brain tumors. J Clin Oncol 13: 2066-2071
3. Della D, Mizutani S, Lamorte G, Goi K, Iwata T and Pierotti MA (1996) p53 activity and chemosensitivity. Nature Med 2: 724-725
4. Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang W-W, Owen-Schaub LB and Roth JA (1994) Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res 54: 2287-2291
5. Glantz MJ, Choy H, Kearms CM, Cole BF, Mills P, Zuhowski EG, Saris S, Rhodes CH, Stopa E and Egorin MJ (1996a) Phase I study of weekly outpatients paclitaxel and concurrent cranial irradiation in adults with astrocytomas. J Clin Oncol 14: 600-609
6. Glantz MJ, Choy H, Akerley W, Kearns CM, Egorin MJ, Rhodes CH and Cole BF (1996b) Weekly paclitaxel with and without concurrent radiation therapy: toxicity, pharmacokinetics, and response. Semin Oncol 23: 128-135
7. Hawkins DS, Demers WG and Galloway DA (1996) Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 56: 892-898
8. Horwitz SB (1992) Mechanism of action of taxol. Trends Pharm Sci 13: 134-136
9. Iwadate Y, Fujimoto S, Sueyoshi K, Tagawa M and Yamaura A (1997) Prediction of drug cytotoxicity in 9L rat brain tumor using flow cytometry with a deoxyribonucleic acid-binding dye. Neurosurgery 40: 782-788
10. Jacks T and Weinberg RA (1996) Cell-cycle control and its watchman. Nature 381: 643-644
11. Kasten MB, Oneykwere O, Sidransky D, Vogelstein B and Craig RW (1991) Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51: 6304-6311
12. Lane DP (1992) p53, guardian of the genome. Nature 358: 15-16
13. Lang FF, Miller DC, Koslow M and Newcomb EW (1994) Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumors. J Neurosurg 81: 427-436
14. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T and Tisty TD (1992) Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70: 923-935
15. Lowe SW, Ruley HE, Jacks T and Housman DE (1993) p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967
16. Murakami Y, Hayashi K and Sekiya T (1991) Detection of aberrations of the p53 alleles and the gene transcript in human tumor cell lines by single-strand conformation polymorphism analysis. Cancer Res 51: 3356-3361
17. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F and Riccardi CA (1991) Rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 139: 271-279
18. Perego P, Giarola M, Righetti SC, Supino R, Caserini C, Delia D, Pierotti MA, Miyashita T, Reed JC and Zunino F (1996) Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 56: 556-562
19. Wahl AF, Donaldson KL, Fairchild C, Lee FYF, Foster SA, Demers GW and Galloway DA (1996) Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nature Med 2: 72-79
20. Walker MD, Green SB, Byar DP, Alexander E Jr, Batzdorf U, Brooks WH, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey J Jr, Owens G, Ransohoff JH, Robertson JT, Shapiro WR, Smith KR Jr, Wilson CB and Strike TA (1980) Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303: 1323-1329
21. Wosikowski K, Regis JT, Robey RW, Alvarez M, Buters JTM, Gudas JM and Bates SE (1995) Normal p53 status and function despite the development of drug resistance in human breast cancer cells. Cell Growth Different 6: 1395-1403
22. Wu GS and El-Deiry WS (1996) p53 and chemosensitivity. Nature Med 2: 255-256